On this page
Back to topGenerate Biomedicines GENB
Generate Biomedicines listed on Nasdaq on 27 Feb 2026 and is not in the S&P 500. It is worth $1.3 billion. Its price history starts on 27 Feb 2026. 9 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 6 other officers are on file. At 30 Jun 2026, Flagship Pioneering was its largest institutional holder, with 48.9% of the company.
- CEO
- Michael Nally
- Listed
- 27 Feb 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Somerville, MA
- Market cap
- $1.3B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Financial history
Twelve months to 30 Sep 2026, from Generate Biomedicines's quarterly filings.
Quarters since Mar 2025
- P/E
- -
- No profit over the last four quarters
Quarterly results
Each quarter's revenue, net income and free cash flow.
Mar 2025 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $4M | $-88M |
| Jun 2026 | $6M | $-67M |
| Mar 2026 | $7M | $-61M |
| Sep 2025 | $10M | $-54M |
| Jun 2025 | $10M | $-52M |
| Mar 2025 | $9M | $-42M |
Generate Biomedicines's market cap since February 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.6B |
Download Generate Biomedicines's data as JSON, with the weekly market caps in billions of dollars from 27 Feb 2026.
Board and leadership
Board and officers
5 people here also hold roles at other S&P 500 companies.
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (9) | |
| Michael NallyChief Executive OfficerAlso at PPG IndustriesLast filed 6 Mar 2026 | |
| Noubar AfeyanDirectorAlso at ModernaLast filed 2 Mar 2026 | |
| Frances ArnoldDirectorAlso at Alphabet | |
| Stephane BancelDirectorAlso at ModernaLast filed 2 Mar 2026 | |
| Marsha FanucciDirectorLast filed 2 Mar 2026 | |
| Jane L. MendilloDirectorLast filed 2 Mar 2026 | |
| Paul Gray ParkerDirectorLast filed 2 Mar 2026 | |
| Nancy A. SimonianDirectorLast filed 2 Mar 2026 | |
| Rupert VesseyDirectorAlso at Bio-TechneLast filed 2 Mar 2026 | |
| Officers (6) | |
| Jason SilversPresident & CFOLast filed 2 Mar 2026 | |
| Gevorg GrigoryanChief Technology OfficerLast filed 2 Mar 2026 | |
| Beth GrousChief People OfficerLast filed 2 Mar 2026 | |
| Aarif KhakooChief Scientific OfficerLast filed 26 Feb 2026 | |
| Laurie Anne LeeChief Medical OfficerLast filed 2 Mar 2026 | |
| Sean MartinChief Legal Officer & GCLast filed 2 Mar 2026 | |
Owners and trading
Largest institutional holders
Each fund group's share of Generate Biomedicines. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $200,712 of stock in 2 sales and bought $150 million in 5 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 29 Oct 2026Sale | Frances ArnoldDirector | $185K |
| 1 Sep 2026Sale | Frances ArnoldDirector | $16K |
| 4 Mar 2026Buy | Michael NallyChief Executive Officer | $240K |
| 2 Mar 2026Buy | Noubar AfeyanDirector | $150M |
| 2 Mar 2026Buy | Jason SilversPresident & CFO | $32K |
| 2 Mar 2026Buy | Jane L. MendilloDirector | $24K |
| 2 Mar 2026Buy | Beth GrousChief People Officer | $5K |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 large insider sale in the last two years.
Insider sales of $1 million or more, and the largest tenth of Generate Biomedicines's insider sales.
Events, newest first
- 29 Oct 2026 Frances Arnold sold $185KDirector
| Date | Event | Filing |
|---|---|---|
| 29 Oct 2026 | Frances Arnold sold $185KDirector | Form 4 |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.